Skip to main content
GRAPPA,PsA,guideline

New Updated GRAPPA Psoriatic Arthritis Recommendations

Jun 29, 2022

The GRAPPA (Group for Research and Assessment of Psoriasis and Psoriatic Arthritis) treatment recommendations have been updated and the 2021 evidence-based guidance is rich in treatment recommendations based on the key disease "domains" - peripheral arthritis, axial disease, enthesitis,

Read Article
psA.fil_.toes_.jpg

Inferior IL-17 Inhibitor Responses in Psoriatic Women

Jun 27, 2022

Pooled data from two large ixekizumab (IXE) trials show that male patients had greater clinical responses than did female patients with psoriatic arthritis are largely unexplored. Reasons for this differential treatment responses to an interleukin-17A inhibitor (IXE) between male and female

Read Article
Treatment of pyoderma gangrenosum is clinically empiric. Full read ref w/ Graded Rx Recommendations: - 1st line: Steriods or Cyclosporin - Consider biologics: TNFi, IL-1, IL-12/23, IL-17, IL-23 - Others: MTX, MMF, AZA, Dap, colchic, thalidomide, IVIG https://t.co/uMJyfFzsRB https://t.co/vw4VqbjZWh
Dr. John Cush @RheumNow( View Tweet )
Jun 25, 2022
hudsonpsoriasis.jpg

Bimekizumab Safety in Psoriasis Patients

Jun 23, 2022

A pooled analyses of data from eight, phase 2 and 3 randomized clinical trials shows bimekizumab, a dual IL-17A/F inhibitor, to be effective in plaque psoriasis and was well tolerated aside from an increased incidence of mild to moderate oral candidiasis. 



The cohort included 1789

Read Article
JAK Janus

JAK/STAT pathway in pyoderma gangrenosum: a new therapeutic highway?

Pyoderma gangrenosum (PG) is rare, but often associated with different forms of arthritis, in particular rheumatoid arthritis and inflammatory bowel diseases. 

Read Article
covid coronavirus virus

Spondyloarthritis and COVID-19

Jun 15, 2022

There are still questions surrounding COVID-19, and some common questions I receive from patients revolve around what to do with their current DMARDs or should they even start treatment during this pandemic. Two studies focused on this question. 

Read Article
guidelines.recommendations.jpg

BSR Guideline for Psoriatic Arthritis - 2022 Update

Jun 06, 2022

The British Society of Rheumatology has published their updated 2022 recommendations for the use of biologics and targeted synthetic treatments in patients iwth psoriatic arthritis. These guidelines follow initial treatment with a single conventional systemic disease-modifying anti-rheumatic

Read Article
exhibitor.floor.ACR

EULAR 2022 – Day 4 Report

Jun 04, 2022

Bags are packed, ready to go, but wait there’s more abstracts to show.



The big news today were the “late breaking” abstracts. This is usually a favorite session of many as this is where the newest of study data often is showcased. 



Here are my favorite late-breakers from Day 4

Read Article
cancer search news magnify

Malignancy risk on b/tsDMARDs in patients with prior malignancy history

Jun 04, 2022

For autoimmune patients with a history of malignancy, the initiation of biologic or targeted synthetic disease modifying agents (bDMARD/tsDMARDs) may provoke concern. While data for biologic medications and malignancy risk has been largely reassuring, clinical trials have often excluded

Read Article
PSA2L.jpg

Key Psoriatic Arthritis topics and updates at EULAR 2022

Jun 04, 2022

At EULAR 2022, I have been looking at topics and presentations in psoriatic arthritis (PsA).  Here are my top picks from this year's meeting.

Read Article
Bimekizumab: IL-17A and F inhibitor for tx of PsA - BE OPTIMAL trial reached primary endpoint: ACR50 44% vs. placebo Efficacy as early as 2 weeks No MACE, uveitis, IBD, deaths @RheumNow #EULAR2022 ABST#LB0001 https://t.co/sHRRwLlChi
Robert B Chao, MD @doctorRBC( View Tweet )
Jun 04, 2022
In vitro study shows Upadacitinib inhibits enthesis T cell derived TNFa and IL-17A, disrupting the prominent IL-23/IL-17/TNFa axis driving SpA. @RheumNow #EULAR2022 ABST#POS0331 https://t.co/pNL3Zlgmt7
Robert B Chao, MD @doctorRBC( View Tweet )
Jun 04, 2022
Phase 3 compared Bimekizumab to PCB and Humira; it met all endpoints for PsA; the drug inhibits both IL17F & IL-17A. Safety signal: increase fungal (candidal) infx #EULAR2022 LB0001 @rheumnow https://t.co/MJJwj44YgU
TheDaoIndex @KDAO2011( View Tweet )
Jun 04, 2022
McInnes @IainBMcInnes1 et al. Bimekizumab (IL17A/Fi) in PsA. BE OPTIMAL 852 patient RCT vs PBO vs ADA. Looks same for joints, better for skin than ADA (not stat sig) @RheumNow #EULAR2022 LB0001 https://t.co/oKEHJE3tGn https://t.co/H7nPnbEWUB
Richard Conway @RichardPAConway( View Tweet )
Jun 04, 2022
Bimekizumab (BKZ) vs PBO at 16 week BE COMPLETE for PsA with inadequate response to TNFi ACR50 44% vs 7%,PASI90 69% vs 7%, ACR20 67% vs 16%, ACR70 27% vs 0.8%, PASI 100 60% vs 5%, MDA 44% vs 6%, no new safety signals #EULAR2022 @RheumNow OP0255 Merola et al https://t.co/riU2sIXGs9
Dr. Antoni Chan @synovialjoints( View Tweet )
Jun 04, 2022
#LB0005 #EULAR2022 Phase 3 RCT of Bimekizumab, dual IL17A and 17F inhibitor in bDMARDs-naive PsA showed significant improvement in ACR50 and PASI90 scores vs Placebo. No major safety signals. Skin response is excellent! @RheumNow https://t.co/yhgB8LGXh6
Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )
Jun 04, 2022
#EULAR2022 LB0001 Bimekizumab (IL-17F and IL-17A) in bionaive PsA BE OPTIMAL phase 3 trial, 24 weeks ⭐️Met Primary endpt - ACR50 ⭐️Met other ACR and PASI endpts ⭐️Safety: higher fungal infections @RheumNow https://t.co/x8u6B93FNl
Jun 04, 2022
BE OPTIMAL Phase 3 RCT Bimekizumab dual IL17A & F inhibitor in bionaive PsA ⭐️ACR50 wk 16 43.9% vs 10% PBO ⭐️PASI 90 wk 16 61% vs. 3% PBO ⭐️separation from wk 4 Safety: fungal injections BKZ > ADA @RheumNow LB0001 #EULAR2022 https://t.co/7ZwV1XDSNb
Aurelie Najm @AurelieRheumo( View Tweet )
Jun 04, 2022
CorEvitas PsA Registry (1000+ pts) Analysis of biologics prescription according to disease domains No real surprise to see that IL-17i were prescribed more frequently in pts w/ PsO BSA>10% at BL Overall first line TNFi 40% > IL-17i 14% POS0309 @RheumNow #EULAR2022 https://t.co/dkLxl8d6ug
Aurelie Najm @AurelieRheumo( View Tweet )
Jun 04, 2022
Castrejon et al. BIOBADASER registry study. Cancer risk with various bDMARDs. Overall I don't think there is a difference here. Lowest in IL17i and highest in abatacept but older and comorbidity confounders @RheumNow #EULAR2022 #POS1439 https://t.co/gfv78ouOTJ
Richard Conway @RichardPAConway( View Tweet )
Jun 03, 2022
EULAR,poster

EULAR 2022 – Day 3 Report

Jun 03, 2022

By now, those of us attending the meeting know how to find a free coffee or sprite, have found comfortable meeting nooks and know our way around! PAnd congrats to you virtual Rheums for mastering the multi-screen, multitask simultaneous consumption posters, tweets and oral abstract presentations

Read Article
Izokibep - potent and small molecule IL-17A inhibitor Phase 2 study in PsA patients Fast onset, met ACR50 primary endpoint AE included site reaction and candida infection @RheumNow #EULAR2022 ABST#OP0258 https://t.co/vZ4xmnhyhl
Robert B Chao, MD @doctorRBC( View Tweet )
Jun 03, 2022
52 wk trial using MSK Ultrasound study on PsA receiving secukinumab showed an early and continued improvement in GLOESS scores. Synovial hypertrophy most responsive. Hands and feet, wrist and knees most affected and responsive. @RheumNow #EULAR2022 ABST#OP0260 https://t.co/jeQezIWLxa
Robert B Chao, MD @doctorRBC( View Tweet )
Jun 03, 2022
Merola et al. BE COMPLETE trial of bimekizumab (dual 17A/17Fi) in TNF-IR PsA. Week 16 ACR50: 43.4% BKZ vs 6.8% PBO. Rapid response with separation from week 4. @RheumNow #EULAR2022 OP0255 https://t.co/ZaxAeePP6L https://t.co/D5mDdkno3c
Richard Conway @RichardPAConway( View Tweet )
Jun 03, 2022
Behrens et al. Izokibep (small molecular size IL17Ai, suggested to abrogate issues with tissue distribution of monoclonal abs) in PsA. ACR50 52% in 80mg, 48% in 40mg, 13% in PBO. @RheumNow #EULAR2022 https://t.co/FUS50ax79C https://t.co/e1n1RbNw1b
Richard Conway @RichardPAConway( View Tweet )
Jun 03, 2022
×